Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1 / 2 EMERALD Study of RTX001 into Spain

Resolution Therapeutics California United Kingdom

of preclinical data on RTX001 at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, held in San Diego from 15-19 November 2024, demonstrating the superior anti-fibrotic and anti-inflammatory effect of IL-10-MMP9 engineered macrophages over non-engineered macrophages. Together, these data underscore the potential of engineered macrophages to address high unmet medical needs in end-stage liver disease.

About RTX001 

RTX001 is an engineered, autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effect. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is being evaluated in the ongoing Phase 1/2 EMERALD study.

About EMERALD

EMERALD is a first-in-human, open-label Phase 1/2 interventional study assessing the safety and efficacy of RTX001 in patients with end-stage liver disease who have recovered from a recent hepatic decompensation. It is conducted in the UK and Spain and began recruiting patients in October 2024. For more information, please visit https://resolution-tx.com/patients/.

About Resolution Therapeutics

Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution's initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.

View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to-expand-phase-12-emerald-study-of-rtx001-into-spain-302309087.html